Results for tag: "LCZ696"

Cardiovascular Drugs are a class of medications used to treat and prevent diseases of the heart and blood vessels. The LCZ696 market is a subset of this class of drugs, specifically targeting the treatment of heart failure. LCZ696 is a combination of two drugs, valsartan and sacubitril, which work together to reduce the strain on the heart and improve its function. It is used to treat patients with chronic heart failure, and has been shown to reduce the risk of hospitalization and death due to heart failure. The LCZ696 market is a rapidly growing one, with many companies competing to develop and market the drug. Companies such as Novartis, AstraZeneca, and Pfizer are all involved in the development and marketing of LCZ696. Other companies, such as Merck, Boehringer Ingelheim, and Sanofi, are also involved in the development and marketing of the drug. Show Less Read more